Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial
Michael A. Koren*, Leyi Lin, Kenneth H. Eckels, Rafael De La Barrera, Vincent Dussupt, Gina Donofrio, Erica L. Sondergaard, Kristin T. Mills, Merlin L. Robb, Christine Lee, Oluwaseun Adedeji, Paul B. Keiser, Justin M. Curley, Nathanial K. Copeland, Trevor A. Crowell, Jack N. Hutter, Melinda J. Hamer, Anais Valencia-Ruiz, Janice Darden, Sheila PeelMihret F. Amare, Tsedal Mebrahtu, Margaret Costanzo, Shelly J. Krebs, Gregory D. Gromowski, Richard G. Jarman, Stephen J. Thomas, Nelson L. Michael, Kayvon Modjarrad
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
6Scopus
citations
Fingerprint
Dive into the research topics of 'Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial'. Together they form a unique fingerprint.